Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2023

Conditions
Refractory Large B-cell Lymphoma
Interventions
BIOLOGICAL

Axicabtagene Ciloleucel

A single infusion of CAR-transduced autologous T cells administered intravenously

DRUG

Rituximab

Administered intravenously

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Trial Locations (14)

10032

Columbia University Medical Center, New York Presbyterian Hospital, New York

32224

Mayo Clinic Florida, Jacksonville

37232

Vanderbilt University Medical Center, Nashville

55905

Mayo Clinic, Rochester

60153

Loyola University Medical Center, Maywood

60637

University of Chicago Medical Center, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

78704

St. David's South Austin Medical Center, Austin

85234

Banner MD Anderson Cancer Center, Gilbert

90404

UCLA Hematology/Oncology, Santa Monica

94305

Stanford Cancer Institute, Palo Alto

98104

Swedish Cancer Institute, Seattle

91010-3012

City of Hope National Medical Center, Duarte

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY

NCT04002401 - Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter